Merck & Co. Heads Into A Year Of Portfolio Expansion

 
• By Jessica Merrill

The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.

branch growing
Merck & Co. could add three new brands to its portfolio this year. • Source: Shutterstock

More from Earnings

More from Business